• Publications
  • Influence
Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy
TLDR
These revised definitions of invasive fungal disease are intended to advance clinical and epidemiological research and may serve as a useful model for defining other infections in high-risk patients. Expand
Treatment of aspergillosis: clinical practice guidelines of the Infectious Diseases Society of America.
TLDR
This research presents a novel, scalable, scalable and scalable approach that allows for real-time evaluation of the impact of Epstein-Barr virus on the development and management of childhood cancer in rats. Expand
CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma.
TLDR
The addition of rituximab to the CHOP regimen increases the complete-response rate and prolongs event-free and overall survival in elderly patients with diffuse large-B-cell lymphoma, without a clinically significant increase in toxicity. Expand
Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis.
TLDR
In patients with invasive aspergillosis,Initial therapy with voriconazole led to better responses and improved survival and resulted in fewer severe side effects than the standard approach of initial therapy with amphotericin B. Expand
Practice Guidelines for the Diagnosis and Management of Aspergillosis: 2016 Update by the Infectious Diseases Society of America.
TLDR
IDSA considers adherence to these guidelines to be voluntary, with the ultimate determination regarding their application to be made by the physician in the light of each patient's individual circumstances. Expand
ESCMID* guideline for the diagnosis and management of Candida diseases 2012: non-neutropenic adult patients.
TLDR
This part of the EFISG guidelines focuses on non-neutropenic adult patients, and liposomal amphotericin B and voriconazole are supported with moderate, and fluconazole with marginal strength for the targeted initial treatment of candidaemia. Expand
Efficacy and safety of voriconazole in the treatment of acute invasive aspergillosis.
TLDR
Voriconazole is efficacious in treating acute IA and is proven and probable in 68 patients, and good responses were seen in 60% of those with pulmonary or tracheobronchial IA and 26% of allogeneic stem cell transplant recipients. Expand
Phase III randomized study of bendamustine compared with chlorambucil in previously untreated patients with chronic lymphocytic leukemia.
TLDR
Bendamustine offers significantly greater efficacy than chlorambucil, and a manageable toxicity profile, when used as first-line therapy in patients with advanced CLL. Expand
Diagnosis and management of Aspergillus diseases: executive summary of the 2017 ESCMID-ECMM-ERS guideline.
TLDR
Treatment duration for aspergillosis is strongly recommended based on clinical improvement, degree of immunosuppression and response on imaging, and in refractory disease, where a personalized approach considering reversal of predisposing factors, switching drug class and surgical intervention is also strongly recommended. Expand
Phase III study to evaluate temsirolimus compared with investigator's choice therapy for the treatment of relapsed or refractory mantle cell lymphoma.
TLDR
Temsirolimus 175 mg weekly for 3 weeks followed by 75 mg weekly significantly improved PFS and objective response rate compared with investigator's choice therapy in patients with relapsed or refractory MCL. Expand
...
1
2
3
4
5
...